LY294002

For research use only.

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

1240 publications

LY294002 Chemical Structure

CAS No. 154447-36-6

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's LY294002 has been cited by 1240 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Targets
CK2 [5]
(Cell-free assay)
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
98 nM 0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells M3uxTGZ2dmO2aX;uJIF{e2G7 M2rjTmlvcGmkaYTpc44hd2ZiSHnzMZRi\2enZDDic5ZqdmViUFmzT{BmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxRTFyIN88UU4> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODl7OEO1NUc,OTB7OUizOVE9N2F-
HeLa cells NWDMZ3lUSmmwZHnu[{Bi\m[rbnn0fUBie3OjeR?= NFrtb3RDcW6maX7nJIFn\mmwaYT5JIZweiCSSUOtb4lv[XOnIHnzc4xifGWmIH\yc40hUGWOYTDj[YxteyxiS3m9OkDPxE1? M2DYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
HeLa cells NUDFR4x1TnWwY4Tpc44h[XO|YYm= NWLlZoZsUW6qaXLpeIlwdiCxZjDtWG9TKHC{b4TlbY4hcXOxbHH0[YQh\nKxbTDI[WxiKGOnbHzzMEBKSzVyPUKuOUDPxE1w M3Pi[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
HeLa (human carcinoma) cells. NVq2OIttTnWwY4Tpc44h[XO|YYm= NF62doRKdiC4aYTyc{BqdmirYnn0bY9vKG:oIFTORU1l\XCnbnTlcpQheHKxdHXpckBscW6jc3WoSG5CNVCNKTDmdo9uKEinTHGgLIh2dWGwIHPhdoNqdm:vYTmgZ4VtdHNuIFnDOVA:OS52IN88UU4> NETwcXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[1PFg4OCd-MUW2OVg5PzB:L3G+
human PC3 cells NVzTSWRlWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHjiUIkzPSEQvF2= NEjxbW0yOjBiaB?= MmjQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNiYYSgNlUhfU1iYX\0[ZIhOTJyIHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gSG1UVw>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjZ6MEG1PUc,OTZ4OECxOVk9N2F-
human BJ cells NUDxS|NHTnWwY4Tpc44h[XO|YYm= MXSyOUDPxE1? M17Gd|IhcA>? MnH5RYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> MnKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5NkewPFUoRjF4N{[3NFg2RC:jPh?=
human BJ cells M{P3O2Z2dmO2aX;uJIF{e2G7 Mo\aNlUh|ryP MkPXNkBp NXXTT4NjUW6qaXLpeIlwdiCxZjDQTVNMKHOrZ37hcIlv\yCrbjDQSGdHNXO2aX31cIF1\WRic3XyeY0he3Sjco\l[EBpfW2jbjDCTkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDsZZNucWRiRVfGVE9RUCCmb33hbY4hd2ZiQXv0JIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHBJNUWJRmCgdoVlcXO2cnnieZRqd25idH:gdIxie22jIH3lcYJz[W6nIHH0JFI2KHWPIITy[YF1\WRiMjDodpMh[mWob4LlJHBFT0ZiY3jhcIxmdmenIHL5JINwdm[xY3HsJI1q[3Kxc3PvdJk> NYHPN|NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3OlcxQDVpPkG2O|Y4ODh3PD;hQi=>
mouse mast cells MlHmSpVv[3Srb36gZZN{[Xl? NHfyU|gzOCEQvF2= NWL6UGVWUW6qaXLpeIlwdiCxZjDTR2YucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDtZZN1KGOnbHzzJIF1KDJyIN88US=> M2P0NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O|QzLz5zNke4PVc1OjxxYU6=
THP1 cells M2G3eGZ2dmO2aX;uJIF{e2G7 NV\VbGw4UW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQh[2inbX;0ZZhqeyCxZjDUTHAyKGOnbHzzMEBKSzVyPUO3JO69VS5? MnPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O|QzRC:jPh?=
mouse Raw264 macrophage M{PSWWZ2dmO2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKEN3YT3t[YRq[XSnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDtc5V{\SCUYYeyOlQhdWGlcn;wbIFo\SxiSVO1NF0yOCEQvF2u NIjkeYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke4PVc1Oid-MU[3PFk4PDJ:L3G+
THP1 cells MofxSpVv[3Srb36gZZN{[Xl? Moe3TY5pcWKrdHnvckBw\iCPQ2CxMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlY2KM7:TT6= M4fwT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O|QzLz5zNke4PVc1OjxxYU6=
THP1 cells MVzGeY5kfGmxbjDhd5NigQ>? MV7Jcohq[mm2aX;uJI9nKFOFRkGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuNFEh|ryPLh?= NGTHRYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke4PVc1Oid-MU[3PFk4PDJ:L3G+
human A375 cells NFPiO2VRem:uaX\ldoF1cW:wIHHzd4F6 MoPsOFYhcA>? NUDhZppvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IES2JIhzeyxiSVO1NF05NjRizszNMi=> NYXWPIxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewOFkzPDhpPkG3NFQ6OjR6PD;hQi=>
HeLa cells NXfXT|hMTnWwY4Tpc44h[XO|YYm= M2LFUmlvcGmkaYTpc44hd2ZiQWitO|UxOyCkaX7kbY5oKHSxIILlZ49u[mmwYX70JHBtczNiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[nliV3XzeIVzdiCkbH;0MEBKSzV;MzFOwG0v M1TQNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUO1NlQ5Lz5zN{GzOVI1QDxxYU6=
human SW480 cells NVfkOIJKTnWwY4Tpc44h[XO|YYm= M3v5clIxKM7:TR?= M4HG[VI1KGh? M1rQTGRm[3KnYYPlJIlvKHO3co\peolvKGW6cILld5Nqd25iaX6gbJVu[W5iU2e0PFAh[2WubIOgZZQhOjBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZY5idHm|aYO= MkPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2N{K5OlIoRjF5NEeyPVYzRC:jPh?=
human A375 cells Mnu5VJJwdGmoZYLheIlwdiCjc4PhfS=> NXHzSYhwUW6qaXLpeIlwdiCxZjDz[ZJ2dS2rbnT1Z4VlKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gRVM4PSClZXzsd{whUUN3ME24MlQh|ryPLh?= NXHNO|lrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFE4OzlpPkG3OlAyPzN7PD;hQi=>
human A2780 cells NIjIeXBCeG:ydH;zbZMh[XO|YYm= NWDabIwyOiEQvF2= MUGxNkBp NXjPNmtCUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBkcXOybHH0bY4uemW|aYP0ZY51KGi3bXHuJGEzPzhyIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJJBpd3OyaH;yfYxifGWmIFHreEBt\X[nbDDheEAzKHWPIHHmeIVzKDF{IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m|Lh?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6NECxPEc,OTd4OESwNVg9N2F-
human H4 cells NH\HSWtHfW6ldHnvckBie3OjeR?= M1\WXVIhcA>? M4TpW2Rm[3KnYYPlJIlvKE[\VlWtVmZRMyC4ZYPpZ4xmKGmwdHXud4l1gSCyZYKgZ4VtdCCrbjDoeY1idiCKNDDj[YxteyCjZoTldkAzKGi{czDy[YxifGm4ZTD0c{Bkd262cn;s MljVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyMkS1PFQoRjF6MEK0OVg1RC:jPh?=
Sf9 cells NHLDXIFHfW6ldHnvckBie3OjeR?= M1z3XGlvcGmkaYTpc44hd2ZiQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVA:Pi57IN88UU4> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN{MUexOkc,OTh|MkG3NVY9N2F-
rat RBL2H3 cells MkfQSpVv[3Srb36gZZN{[Xl? NWrEWZRtUW6qaXLpeIlwdiCxZjDBNlMyQDdvaX7keYNm\CCmZXfyZY52dGG2aX;uJIlvKHKjdDDSRmwzUDNiY3XscJM> NXn4fmFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNlg4OTZpPkG4N|I5PzF4PD;hQi=>
human U87MG cells NVjXe2pvTnWwY4Tpc44h[XO|YYm= NVnseZh3UW6qaXLpeIlwdiCxZjDHV2s{NWKndHGgbY4hcHWvYX6gWVg4VUdiY3XscJMh[nliRVzJV2EtKEmFNUC9PE4yKM7:TT6= MnL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|NEW2NFkoRjF6M{S1OlA6RC:jPh?=
human H460 cells MW\GeY5kfGmxbjDhd5NigQ>? MoXwN|Ah|ryP NFfGS5hKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hUDR4MDDj[YxteyCjc4Pld5Nm\CCjczDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOncjC0O|MhfXBidH:gN|AhfU1? NV[5TFlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NFE3ODFpPkG4OVAyPjBzPD;hQi=>
human U251HRE cells NFqwdXBHfW6ldHnvckBie3OjeR?= Ml3WTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMTDhZ5RqfmG2aX;uJIlvKGi3bXHuJHUzPTGKUlWgZ4VtdHNiYomgZ4VtdCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6 NH3HcWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEWwNVYxOSd-MUi1NFE3ODF:L3G+
human 184B5 cells NVfrbndzS3m2b4TvfIlkyqCjc4PhfS=> MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxPFRDPSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OzlwM{eg{txONg>? NVr0Z5I4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-468 cells M4SxXGN6fG:2b4jpZ:Kh[XO|YYm= M4qxO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZpkhW1KEIHHzd4F6NCCLQ{WwQVExNjRizszNMi=> NFi1XFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MDA-MB-468 cells Mn;zR5l1d3SxeHnjxsBie3OjeR?= M3PGOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUiuNkDPxE1w NIO1RlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MDA-MB-231 cells MkXPR5l1d3SxeHnjxsBie3OjeR?= NUHjOHRGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Pi55MTFOwG0v NEDXUYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MDA-MB-468 cells NX;LOWdzS3m2b4TvfIlkyqCjc4PhfS=> MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3Ojef-8kEBKSzVyPUSuO|Yh|ryPLh?= NUTHZ4JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells NFPvWGdEgXSxdH;4bYPDqGG|c3H5 MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD12LkO1JO69VS5? MlT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-231 cells NE\iRmFEgXSxdH;4bYPDqGG|c3H5 NWrJWINRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEDPxE1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSU2zMlMzKM7:TT6= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MCF7 cells NHLRNIhEgXSxdH;4bYPDqGG|c3H5 NXLN[JZFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKRTNwMU[g{txONg>? NIjHNGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MCF7 cells NUTQZ3NTS3m2b4TvfIlkyqCjc4PhfS=> NHTvd3ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFExKHWPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0{NjB6IN88UU4> Mlm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MCF7 cells MXPDfZRwfG:6aXRCpIF{e2G7 NVz5XG5lS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCrbjDwdoV{\W6lZTDv[kAzOCEQvF2gZ4htd3KxcYXpcoUh[nliU2LCJIF{e2G7LDDHTVUxRTJwNkOg{txONg>? NVHIS|dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
Sf21 cells NFjnSJhHfW6ldHnvckBie3OjeR?= MmCwTY5pcWKrdHnvckBw\iCvb4Xz[UBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoMkGgZ4VtdHNuIFnDOVA:OC53IN88UU4> MlTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEiyOlkoRjF7N{S4NlY6RC:jPh?=
Sf9 cells Mnjo[ox2d3Knc3PlcpQheG:uYYLpfoF1cW:wIHHzd4F6 MkjPTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDifUBndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? M2O4dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUKxOlMyLz5{MUGyNVY{OTxxYU6=
Sf9 cells MVHGcJVwemW|Y3XueEBxd2yjcnn6ZZRqd25iYYPzZZk> NWrjVYREUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO|YYmsJGlEPTB;MD61OUDPxE1w MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N|E9N2F-
human IGROV1 cells MoDGSpVv[3Srb36gZZN{[Xl? M1XESlI1KGh? M1PZVWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgOUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 NVrncpBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human IGROV1 cells NWfueVhqTnWwY4Tpc44h[XO|YYm= MVqyOEBp NXi3XHhOS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUUeUT2[xJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNUBxcGG|ZTDheEAyKG[xbHSgTWM2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2com= MnuxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells NWXUe4RUTnWwY4Tpc44h[XO|YYm= MoDHNlQwPDhiaB?= Ml7PTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY4njcIlvKERzIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NFX0Tpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human IGROV1 cells NWe5b3JoTnWwY4Tpc44h[XO|YYm= M3vLe|I1NzR6IHi= MX;Jcohq[mm2aX;uJI9nKFCLM1uvRYt1KGmwIHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RibHX2[Ywh[XRiMTD0c{A2KHSrbXXzJGlEPTBiYX\0[ZIhOjRidH:gOFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NGXrR4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human HCT116 cells MWLDfZRwfG:6aXRCpIF{e2G7 NFXQ[oo4OiCq M1q1XGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVU3NjBzIN88UU4> MmPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEWyOVAoRjJzOUS1NlUxRC:jPh?=
human KB cells MWHDfZRwfG:6aXRCpIF{e2G7 NV31dll[PzJiaB?= NW[0XY5XS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20OE44PiEQvF2u MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2NUK1NEc,OjF7NEWyOVA9N2F-
HUVEC NUHXOIZzTnWwY4Tpc44h[XO|YYm= MmjyNVAuOjVizszN NWe3[mNxOzBibXnu M4fiVmlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDoeY1idiCLQ1HNMVEheHKxbX;0[ZIh[WO2aY\peJkh\XiycnXzd4VlKGmwIFjVWmVEKGG|c3Xzd4VlKGG|IHLleIEu\2GuYXP0c5Nq\GG|ZTDhZ5Rqfmm2eTDheEAyOCC2bzCyOUB2VSCycnX0doVifGWmIH\vdkA{OCCvaX7zJIJm\m:{ZTDUUmZidHCqYTDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 NXPXSlB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlY1OTBpPkKyNFI3PDFyPD;hQi=>
HUVEC Mlq5SpVv[3Srb36gZZN{[Xl? MlfTNVAuOjVizszN NHj1[mMyPiCq NILMUoJKdmirYnn0bY9vKG:oIGTOSoFteGijLYP0bY12dGG2ZXSgTWNCVS1zIH3SUmEh\XiycnXzd4lwdiCrbjDIWXZGSyCjdDCxNEB1dyB{NTD1UUBxemW2cnXheIVlKG[xcjCxOkBpenNiYnXmc5JmKFSQRnHsdIhiKGOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkA3KGi{czDifUBTXC2SQ2KgZY5idHm|aYO= M4HUVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK2OFExLz5{MkCyOlQyODxxYU6=
human HCT116 cells NE\QUYFHfW6ldHnvckBie3OjeR?= NYf4T3RMOTBizszN NUj0dYtIUW6qaXLpeIlwdiCxZjDBb5Qh\XiycnXzd4lwdiCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZQhOTBidV2gZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NEfi[5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells MX;GeY5kfGmxbjDhd5NigQ>? NF61SXYyOCEQvF2= MkewTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd|IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz NXvKWFkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells MXvGeY5kfGmxbjDhd5NigQ>? NYjp[5oyOTBizszN M2\XWmlvcGmkaYTpc44hd2ZiUFmzT4FteGijIHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGFsfCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIF1KDFyIIXNJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells M{LWNWZ2dmO2aX;uJIF{e2G7 Mmn2NVAh|ryP NWHQ[nB2OTBibXnu M{PHNmlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFixNFQ4WiCvdYThcpQhcW5iaIXtZY4hUEOWMUG2JINmdGy|IIXzbY5oKFt|MmDdRXRRKGG2IEGwJJVOKGGodHXyJFExKG2rboO= NVXXeIptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells M{[wXGZ2dmO2aX;uJIF{e2G7 MUmxNEDPxE1? M3TMSVExKG2rbh?= NIOw[JlKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMhfXOrbnegX|MzWF2DVGCgZZQhOTBidV2gZYZ1\XJiMUCgcYlvew>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells NVLqNpMyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVS0PEBp MonpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[uO{DPxE1w MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells NX3RZVJ7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEHVNmU1QCCq M4m3emdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2u MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells NGLyOJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH7rTnA1QCCq MkjYS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBJOTB2N2KgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS5|IN88US=> M2rDT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human A549 cells M{HTUWN6fG:2b4jpZ:Kh[XO|YYm= MVW3NkBp MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYm= Mn[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEC4OVEoRjJ{NEiwPFUyRC:jPh?=
human PC3 cells M1HXb2N6fG:2b4jpZ:Kh[XO|YYm= NFj0UIg4OiCq M{fae2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[xMlM2KM7:TT6= Ml3jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEC4OVEoRjJ{NEiwPFUyRC:jPh?=
human HL60 cells M1r3VWN6fG:2b4jpZ:Kh[XO|YYm= NVrSV493PzJiaB?= MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT65OEDPxE1w M{LtU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
Sf21 cells MXfGeY5kfGmxbjDhd5NigQ>? NXXIUY45UW6qaXLpeIlwdiCxZjDtc5V{\SC5aXzkJJR6eGViUFmzT4FteGijIHX4dJJme3OnZDDpckBU\jJzIHPlcIx{KGOxLXX4dJJme3OrbnegUk11\XKvaX7hcEBJcXNvdHHn[4VlKGi3bXHuJJA5PWFidYPpcochVC2jbIDoZU1xcG:|cHjheIllgWyrbn;zbZRwdCC|dXLzeJJifGViYomgWGxEKGKjc3XkJJBpd3OyaH;yJIlu[WerbnesJGlEPTB;MD61JO69VQ>? M2jqelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUKwOlMxLz5{MkWyNFY{ODxxYU6=
HEK293 cells NF;rVXJHfW6ldHnvckBie3OjeR?= NX6zT2Z4OS53IHi= MYrEbZNxdGGlZX3lcpQhd2ZiW{PIYWxUTCCocn;tJIh2dWGwIEXIWFYhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bi\nSncjCxMlUhcHK|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5o NIiwNIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWzO|E2Oyd-MkK1N|cyPTN:L3G+
human H1299 cells M4jVfGZ2dmO2aX;uJIF{e2G7 M1\Y[lAvOS1|MDFOwG0> NUH5e3hbOjRiaB?= MljQTY5lfWO2aX;uJI9nKEqQSz3t[YRq[XSnZDDDTG9RKGW6cILld5Nqd25iaX6gbJVu[W5iSEGyPVkh[2WubIOgZZQhOC5zIITvJFMxKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NIL2TY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[yNlA3QSd-MkK2NlIxPjl:L3G+
human H1299 cells MmPiSpVv[3Srb36gZZN{[Xl? M3PpTVAvOS1|MDFOwG0> NWXiXpE2OjRiaB?= M33TdGlv\HWldHnvckBw\iCGUkWg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? M2Hu[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkKyNFY6Lz5{Mk[yNlA3QTxxYU6=
human H1299 cells NXvzdmpRTnWwY4Tpc44h[XO|YYm= M1XXPVAvOS1|MDFOwG0> NWnBTWpGOjRiaB?= NHHOTZBFd3ewIILl[5Vt[XSrb36gc4Yh[0mDUEKg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kAyODBidXevcYwhXFKDSVygZY5lKFCLM1ugbY5pcWKrdH;yJGx[Ojl2MECy MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells MX7GeY5kfGmxbjDhd5NigQ>? NYHDSWxQOC5zLUOwJO69VQ>? MkjsNlQhcA>? MoK5SI94diC{ZXf1cIF1cW:wIH;mJINKSVB{IHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M{n3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkKyNFY6Lz5{Mk[yNlA3QTxxYU6=
MDA-MB-231 cells NEf0THdE\WyuIHnueoF{cW:wIHHzd4F6 MXWyOEBp M37rPGlvcGmkaYTpc44hd2ZiZYDpeIhmdGmjbDDndo94fGhiZnHjeI9zNWmwZIXj[YQh[2WubDDtbYdz[XSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDwdoUucW6ldXLheIVlKG[xcjCyOEBpenNiYomgZ4VtdCCrbo\hd4lwdiCjc4PhfUwhUUN3ME2wMlM5KM7:TT6= NFTTV2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwOFExQCd-MkK4NFQyODh:L3G+
human LNCAP cells NEjnTGZHfW6ldHnvckBie3OjeR?= NWW4SGp4OC5zLUOwJO69VQ>? M{\IfVI1KGh? NUHSO5BWTG:5boLl[5Vt[XSrb36gc4Yhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDoeY1idiCOTlPBVEBk\WyuczDheEAxNjFidH:gN|AhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NHj3dIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizNlMyPid-MkK4N|I{OTZ:L3G+
human LNCAP cells NFLtb4RHfW6ldHnvckBie3OjeR?= NF:zNHgxNjFvM{Cg{txO MWmzNEBucW5? NXPFXZpbUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCzNEBucW6|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MlXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{KzNVYoRjJ{OEOyN|E3RC:jPh?=
human PC3 cells NGTkS21HfW6ldHnvckBie3OjeR?= NHH1b4Y2OCEQvF2= MoXUPEBp NY\oNlN4UW6mdXP0bY9vKG:oIICyNUBxem:2ZXnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hWEN|IHPlcIx{KGG2IEWwJJVOKGmwY4XiZZRm\CCob4KgPEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=> M4HNNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUm4OFczLz5{Mkm5PFQ4OjxxYU6=
human BT474 cell MVfQdo9tcW[ncnH0bY9vKGG|c3H5 NGn6VXg4OiCq MnXiTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch|ryPLh?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMECwOUc,OjN2MUCwNFU9N2F-
human PC3 cell NULEb4pIWHKxbHnm[ZJifGmxbjDhd5NigQ>? NF\RbIQ4OiCq MXHJcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yOi5zIN88UU4> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMECwOUc,OjN2MUCwNFU9N2F-
human PC3 cells NFjRTXBHfW6ldHnvckBie3OjeR?= M2P4UlMxKG2rbh?= M2LvN2lvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBRSzNiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gRWtVKHCqb4PwbI9zgWyjdHnvckBifCC|ZYLpcoUhPDd|IHHmeIVzKDNyIH3pcpMh[nliRVzJV2EtKEmFNUC9NU4{|ryPLh?= M{fQNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEGwNFA2Lz5{M{SxNFAxPTxxYU6=
human MGC803 cells NY\3eZdyTnWwY4Tpc44h[XO|YYm= NIHoVVAzPSEQvF2= M3nEWVQ5KGh? NInJUZZE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBOT0N6MEOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgZZQhOjVidV2gZYZ1\XJiNEigbJJ{KHW|aX7nJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZYZ1\XJiNEigbJJ{KGK7IH\sc5ch[3m2b33leIVzKHKnbHH0bZZmKHSxIHPvcpRzd2x? MmrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUm4OlkoRjJ2MUG5PFY6RC:jPh?=
mouse RAW264.7 cells Mo\6SpVv[3Srb36gZZN{[Xl? NHzxOHAzPSEQvF2= MYCyNEBp Mk\OTY5pcWKrdHnvckBw\iCSSUPLM2FMXCCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2OgdJJwfGWrbjDlfJBz\XO|aX;uJIF1KDJ3IN88UUBi\nSncjCyNEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NGTJUo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5PVYyPid-MkSyPVk3OTZ:L3G+
human A549 cells NFHCNYpRem:uaX\ldoF1cW:wIHHzd4F6 M1jTR|czKGh? NI\McI9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OEKuN|Ih|ryPLh?= NGfObWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HuH7 cells M3LFWXBzd2yrZnXyZZRqd25iYYPzZZk> MVm3NkBp M1TGO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD14Nz6xPEDPxE1w MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7M{e4O{c,OjV4OUO3PFc9N2F-
human HCT116 cells MXTQdo9tcW[ncnH0bY9vKGG|c3H5 NEXwW5k4OiCq MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13MT64NkDPxE1w NGPO[Vk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HL60 cells MWXQdo9tcW[ncnH0bY9vKGG|c3H5 MmfHO|IhcA>? NFjB[5VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUiuOFMh|ryPLh?= MmTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO|g4RC:jPh?=
Sf9 cells NVzZTJFLTnWwY4Tpc44h[XO|YYm= NXnROIU6UW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJIh2dWGwIFPLNkBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxKD1iNj65JO69VS5? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODl7OEO1NUc,OTB7OUizOVE9N2F-
HeLa cells MmnvSpVv[3Srb36gZZN{[Xl? MnHJTY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NixiSVO1NEA:KDFwNDFOwG0v MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjl2MUOzPUc,OTJ7NEGzN|k9N2F-
HeLa cells MULGeY5kfGmxbjDhd5NigQ>? NGruN2FKdmirYnn0bY9vKG:oIFTORUBl\XCnbnTlcpQheHKxdHXpckBscW6jc3WgbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy|LDDJR|UxKD1iMT61JO69VS5? MnLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O|AoRjF3NkW4PFcxRC:jPh?=
Sf21 cells NFnTPGdHfW6ldHnvckBie3OjeR?= NG[zfItKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy|LDDJR|UxKD1iMD65JO69VS5? Ml6yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEiyOlkoRjF7N{S4NlY6RC:jPh?=
Sf21 cells MV;GeY5kfGmxbjDhd5NigQ>? NGTXV3BKdmirYnn0bY9vKG:oIHLveolv\SC{ZXPvcYJqdmGwdDDQTVNM\2GvbXGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|LXnu[oVkfGWmIGPmNlEh[2WubIOsJGlEPTBiPTC3JO69VS5? MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEiyOlkoRjF7N{S4NlY6RC:jPh?=
HeLa cells M3u2OmZ2dmO2aX;uJIF{e2G7 NFXNWohC[3Srdnn0fUBifCCSSUPLJIlvKGi3bXHuJGhmVGFiY3XscJMh[nliRVzJV2EtKEWFNUCgQUAyNjVizszNMi=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB7MkOyN{c,OjByOUKzNlM9N2F-
Sf21 cells NXe5OpJtTnWwY4Tpc44h[XO|YYm= NYjSNoM1UW6qaXLpeIlwdiCxZjDQTVNM\GWudHGg[ZhxemW|c3XkJIlvKGOnbHzzJINwNWW6cILld5NqdmdiTj30[ZJucW6jbDDIbZMufGGpZ3XkJIh2dWGwIIC4OYEhfXOrbnegUE1idHCqYT3wbI9{eGijdHnkfYxqdm:|aYTvcEB{fWK|dILheIUh[nliVFzDJIJie2WmIIDoc5NxcG:{IHntZYdqdmduIFnDOVAhRSByLkW3JO69VS5? NIPyclM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWyNFY{OCd-MkK1NlA3OzB:L3G+
Sf21 cells M4i0U2Z2dmO2aX;uJIF{e2G7 NHqx[ZRKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCSSUPLZoV1[SCneIDy[ZN{\WRiaX6gV4YzOSClZXzsd{Bkdy2neIDy[ZN{cW6pIF6teIVzdWmwYXygTIl{NXSjZ3fl[EBpfW2jbjDwPFViKHW|aX7nJGwu[WyyaHGtdIhwe3CqYYTp[JltcW6xc3n0c4whe3Wkc4TyZZRmKGK7IGTMR{Bj[XOnZDDwbI9{eGixcjDpcYFocW6pLDDJR|UxKD1iMD65O{DPxE1w NI\lUGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWyNFY{OCd-MkK1NlA3OzB:L3G+
HL60 cells M4PEemFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NXzWOY4{OyCmYYnz MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF2IN88UU4> M1S2elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
U937 cells MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NWXXc5R5OyCmYYnz M3HwcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMUSg{txONg>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
Jurkat cells MmP4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVuzJIRigXN? MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEq3cnvheEBk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMkKg{txONg>? M4P1W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
K562 cells MlLtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlPNN{Bl[Xm| M3WwW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iM{ig{txONg>? NGDYfJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U266 cells MljBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVnJfnh7OyCmYYnz MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV{Nk[gZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDR4IN88UU4> NF\xWm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
MDA-MB-231 cells M{fBSmFvfGmvaXfyZZRwenliYYPzZZk> M1qzVFI1KGi{cx?= MYLBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGGpYXnud5QhTUeIIHnu[JVk\WRiY3jlcY91[XirczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIDy[Ylv[3WkYYTl[EBnd3JiMkSgbJJ{KG[xbHzve4VlKGK7IFXHSkBi\GSrdHnvckBnd3JiMz61JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxKD1iMD6zPEDPxE1w NV7Cblh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVgzOzdpPkK3OVk5OjN5PD;hQi=>
MDA-MB-231 cells NEnuVWVCdnSraX72ZZNqfmViYYPzZZk> MWezMlUhcHK| MWnBcpRqcW64YYPpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVITi2rbnT1Z4VlKGOnbHygbY53[XOrb36gZYZ1\XJiMz61JIhzeyxiSVO1NEA:KDBwM{ig{txONg>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDByOUWyNUc,OjhyMEm1NlE9N2F-
HEK293T cells MnTHSpVv[3Srb36gZZN{[Xl? NG\BSHEyKGi{ M3ztWmlvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2KndHGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDpcoN2[mG2ZXSg[o9zKDFiaIKgZpkhVENvTWOvUXMh[W6jbInzbZMtKEmFNUCgQUAxNjR{IN88UU4> M2jiVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
HEK293T cells NIHYXpRHfW6ldHnvckBie3OjeR?= M{HIelEhcHJ? MYDJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tl\Wy2YTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOSCqcjDifUBNSy2PUz;NV{BidmGueYPpd{whUUN3MDC9JFEvPTNizszNMi=> M{TOSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
HEK293T cells NXOwbllRTnWwY4Tpc44h[XO|YYm= M2\tOFEhcHJ? MV\Jcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tidHCqYTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOSCqcjDifUBNSy2PUz;NV{BidmGueYPpd{whUUN3MDC9JFIvOzdizszNMi=> NGf1Zpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
MDA-MB-231 cells NHHIN|RHfW6ldHnvckBie3OjeR?= NFfjdVFKdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJIlvfmG|aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5|ODFOwG0v MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNyMkSwNUc,Ojh|MEK0NFE9N2F-
MCF7 cells MXzGeY5kfGmxbjDhd5NigQ>? MXKxNEB2VQ>? M{X5OVEhcHJ? Mn7ZTY5pcWKrdHnvckBw\iCLR1[xVkBxcG:|cHjvdplt[XSrb36gZZQhXHm{MUG2NUBz\XOrZIXlJIlvKGi3bXHuJG1ETjdiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNUBpeiCkeTDIc4VkcHO2IEOzNlU5KHO2YXnubY5oKGKjc3XkJIludXWwb3jpd5Rw[2inbXnjZYwh[W6jbInzbZM> MlvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
SKOV3 cells MkXMSpVv[3Srb36gZZN{[Xl? MWSyNEB2VQ>? MnzRNlQhcHK| MUTJcohq[mm2aX;uJI9nKEKGTl[tbY5lfWOnZDDpcpZie2mxbjDpckBpfW2jbjDTT29XOyClZXzsd{BifCB{MDD1UUBi\nSncjCyOEBpenNiaX6gZpkhdWG2cnnn[YwhcW64YYPpc44h[XO|YYm= NUjiT4xZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNlI1QDRpPkK5NVIzPDh2PD;hQi=>
SKOV3 cells M{m3XWFvfGmvaXfyZZRwenliYYPzZZk> NUHH[oVpOjBidV2= NXi4WHZ6OjRiaILz NETafYhCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCERF7GMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25iYYSgNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KHOlcnH0Z4ghf2:3bnSgbIVidGmwZzDhd5NigQ>? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF{MkS4OEc,OjlzMkK0PFQ9N2F-
NB1643 cells MU\xTHRUKGG|c3H5 NUTCToQ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 cells Mo\tdWhVWyCjc4PhfS=> MkTidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 cells NXG3OYdueUiWUzDhd5NigQ>? MnPIdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC cells M4jrZpFJXFNiYYPzZZk> MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= MlPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
J774 cells NGHrTZhCdnSraX7mcIFudWG2b4L5JIF{e2G7 MlHPNlQhcHK| MnjERY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDKO|c1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDMVHMucW6mdXPl[EBOS1BzIHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hOy55IN88UU4> Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5Mk[2PFAoRjJ7N{K2OlgxRC:jPh?=
J774 cells NGfaTHNCdnSraX7mcIFudWG2b4L5JIF{e2G7 M3vMNFI1KGi{cx?= NEXrZWlCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJGo4PzRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGxRWy2rbnT1Z4VlKEmONjDlfJBz\XO|aX;uJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiSVO1NEA:KDVwMTFOwG0v NGnTOFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUeyOlY5OCd-Mkm3NlY3QDB:L3G+
J774 cells NUmw[Vl4SW62aXnu[oxidW2jdH;yfUBie3OjeR?= MkO5NlQhcHK| NYnoeGI2SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBLPzd2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBNWFNvaX7keYNm\CCwaYTybYMhd3irZHWgdJJw\HWldHnvckBi\nSncjCyOEBpenNiYomgS5Jq\XO|IHHzd4F6NCCLQ{WwJF0hQC57IN88UU4> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells MWTGeY5kfGmxbjDhd5NigQ>? MWmxNEB2VQ>? NX24UGdlPCCqcoO= NXLqOHp{UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBud3W|ZTDKO|c1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDMVHMucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlQ4OyCjdDCxNEB2VSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NVnvTmx[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NlY3QDBpPkK5O|I3PjhyPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
E-cadherin / p-Akt / Akt; 

PubMed: 29731993     


Immunoblot analysis of E-cadherin, P-AKT, and AKT in SNU-C5/5-FU cells treated with LY294002 (20 μM).

beta-catenin / p-GSK3β / Cyclin D1; 

PubMed: 29731993     


Immunoblot analysis of P-AKT, AKT, β-catenin, P-GSK-3β, GSK-3β, and cyclin D1 in SNU-C5/5-FU cells treated with LY294002 (20 μM).

Bcl-xl / Bax / caspase3 / cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of LY294002 for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin; 

PubMed: 23251002     


HT29, Colo205, and RKO cells were treated for 2 h with PLX4720, LY294002 or their combination at indicated concentrations. Cell lysates were subjected to western blot analysis with antibodies against phosphorylated or total forms of AKT or ERK1/2, and antibodies against p-P70S6K, pGSK3β or vinculin.

pPKB-S473; 

PubMed: 20649566     


Typical Western blot showing that basal pPKB-S473 was reduced by increasing concentrations of LY294002 (upper panel). Pre-incubating 10 µM of the MEK-1/2 inhibitor U0126 induced pPKB–S473 levels which were reduced when rising concentrations of LY294002 were added. A full suppression of pPKB–S473 below the detection limit was seen at 30 µM PI3K inhibitor (10 µM U0126 + 30 µM LY294002). β-Actin immunoreaction served as loading control.

29731993 25344912 23251002 20649566
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of LY294002 on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
Immunofluorescence
α-SMA / CD31; 

PubMed: 27671604     


Immunofluorescence analysis for the expression levels of CD31 and α-SMA in Control, LY294002, As2O3 and As2O3 + LY294002 groups. Scale bar = 30 μm. (in HAECs).

E-cadherin / beta-catenin; 

PubMed: 29731993     


The localization of E-cadherin and β-catenin were confirmed by confocal microscopy. Scale bars, 20 μm.

COX-2 / p-NFκB; 

PubMed: 29731993     


The localization of Cox-2 and P-NF-κB was confirmed by confocal microscopy. Scale bars, 20 μm.

FOXO3a; 

PubMed: 18388194     


C2C12 cells were plated into two-well chamber sliders for 24 h and then treated with 20 μm LY294002 or the same amount of vehicle (ethanol) for 16 h. Cells were fixed and FOXO3a was stained. LY294002 treatment activates FOXO3a and leads its translocation into the nucleus.

27671604 29731993 18388194
ELISA
IL-10 / IL-1β / TNFα / IL-6; 

PubMed: 22208359     


Microglial cells were pre-treated with LY294002 for 1 h and then stimulated with LPS (100 ng/ml) or PIC (10 μg/ml) for 16 h. ELISA were performed. All values were normalized to those obtained in cultures stimulated with LPS or PIC without LY294002 (= 1). At least 3 cases were analyzed for each experiment, and statistics were performed using t-test comparing values with vs. without LY294002.

22208359
In vivo LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol

Kinase Assay:

[4]

- Collapse

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:

[2]

- Collapse
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286
Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • Answer:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • Question 2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID